Researcher

    Amélie Marsot , Ph.D.

    amelie.marsot@umontreal.ca
    Amélie Marsot
    Research Axis
    Infectious Diseases and Acute Care Axis
    Research Theme
    Clinical pharmacology

    Phone
    514-343-6111 ext.3253

    Online

    Title

    • Associate Professor, Faculty of Pharmacy, Université de Montréal (2023)
    • Associate researcher, CHU Sainte-Justine Research Centre

    Education

    • University Diploma, Medical Pedagogy, Aix Marseille Université, 2013
    • PhD, Clinical Research and Public Health, Aix Marseille Université, 2012
    • Inter-University Diploma, Training of Investigators in Clinical Trials, Aix Marseille Université, 2011
    • Master 2, Pharmacokinetics, Aix Marseille Université, 2009

    Research Interests

    Anti-infectives are among the most commonly used therapeutic agents. Therapeutic drug monitoring (TDM) combines quantification of drug concentrations in the blood, pharmacological interpretation and therapeutic guidance. In the era of precision medicine and the emergence of antimicrobial resistance, TDM combined with pharmacokinetic/pharmacodynamic population models is enabling the development of model-informed precision dosing, and is playing an increasingly important role in treatment optimization.

    My research project aims to develop a model-informed precision dosing program for anti-infectives. This program focuses more specifically on improving the quality of care in vulnerable populations (pediatrics, intensive care units, etc.). This research program, subdivided into four distinct and complementary axes, will enable the development of model-informed precision dosing of many anti-infectives not currently available in Quebec and Canada, in order to individualize dosages and optimize pharmacotherapy.

    Research Topics

    • Pharmacometrics
    • Therapeutic drug monitoring
    • Clinical pharmacology
    • Anti-infectives

    Career Summary

    PhD holder in clinical research and public health in pharmacokinetics and author of some 50 scientific articles, Amélie Marsot is Associate Professor and Director of the STP2 Laboratory in the Faculty of Pharmacy at the Université de Montréal. She was previously a researcher in the Clinical Pharmacology Department of Assistance publique - Hôpitaux de Marseille and a part-time lecturer at the Aix-Marseille University.

    Laboratory

    STP2 Lab

    Awards and Distinctions

    • Excellence Award, Teaching, Faculté de Pharmacie, Université de Montréal – 2023
    • Excellence Award, Teaching, Faculté de Pharmacie, Université de Montréal – 2022
    • Young Researcher Award, Technology and Sciences, Agence Universitaire de la Francophonie – 2019
    • Thesis Award, Société Française de Pharmacologie et Thérapeutique - 2011

    Presentations

    • Pharmacocinétique des aminoglycosides dans la fibrose kystique. Édition 2023 du Symposium québécois des chercheurs et cliniciens FK, 12 mai 2023, Montréal
    • Optimisation des doses : Apport de la pharmacocinétique. Colloque 135, 90e congrès de l’ACFAS, 8 mai 2023, Montréal
    • De l’antibiorésistance à l’antibiogouvernance : Place de la pharmacothérapie personnalisée. Entretiens Jacques Cartier 6 novembre 2019, Université de Montréal
    • PK/PD des bêta-lactamines en unités de soins intensifs. Réunion recherche soins intensifs CHUM, 4 novembre 2019, CHUM
    • Suivi thérapeutique pharmacologique et pharmacocinétique – Réunion scientifique Département de Pharmacie CHU Sainte Justine – 9 Janvier 2019, Montréal

    Publications

    • β-Lactam Pharmacokinetic/Pharmacodynamic Target Attainment in Intensive Care Unit Patients: A Prospective, Observational, Cohort Study. Guilhaumou R, Chevrier C, Setti JL, Jouve E, Marsot A, Julian N, Blin O, Simeone P, Lagier D, Mokart D, Bruder N, Garnier M, Velly L. Antibiotics (Basel). 2023 Aug 5;12(8):1289. doi: 10.3390/antibiotics12081289.PMID: 37627709
    • Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting. Greppmair S, Brinkmann A, Roehr A, Frey O, Hagel S, Dorn C, Marsot A, El-Haffaf I, Zoller M, Saller T, Zander J, Schatz LM, Scharf C, Briegel J, Minichmayr IK, Wicha SG, Liebchen U. Intensive Care Med. 2023 Aug;49(8):966-976. doi: 10.1007/s00134-023-07154-0. Epub 2023 Jul 13.PMID: 37439872
    • External Evaluation of Population Pharmacokinetic Models for Precision Dosing: Current State and Knowledge Gaps. El Hassani M, Marsot A. Clin Pharmacokinet. 2023 Apr;62(4):533-540. doi: 10.1007/s40262-023-01233-7. Epub 2023 Apr 1.PMID: 37004650
    • Tobramycin a Priori Dosing Regimens Based on PopPK Model Simulations in Critically Ill Patients: Are They Transferable? Duong A, Simard C, Williamson D, Marsot A. Ther Drug Monit. 2023 Oct 1;45(5):616-622. doi: 10.1097/FTD.0000000000001091. Epub 2023 Mar 7.PMID: 36917735
    • Development and Evaluation of a Height-Based Tobramycin Initial Dosing Nomogram for the Treatment of Adult Cystic Fibrosis Pulmonary Exacerbations. El Hassani M, Thirion DJG, Koloskoff K, Matouk E, Simard C, Cloutier I, Pilote S, Marsot A. Ther Drug Monit. 2023 Apr 1;45(2):259-264. doi: 10.1097/FTD.0000000000001053.PMID: 36730982
    • VANCOmycin dose adjustments comparing trough levels to the ratio of the area under de curve to the minimum inhibitory concentration method using a BAYESian approach: A feasibility study. Bilodeau V, Huot J, Perreault C, Haraoui LP, Delorme C, Poudrette J, Marsot A, Crevier B.J Clin Pharm Ther. 2022 Dec;47(12):2335-2344. doi: 10.1111/jcpt.13818. Epub 2022 Dec 2.PMID: 36461655
    • Impact of piperacillin unbound fraction variability on dosing recommendations in critically ill patients. El-Haffaf I, Guilhaumou R, Velly L, Marsot A.Br J Clin Pharmacol. 2023 Apr;89(4):1502-1508. doi: 10.1111/bcp.15619. Epub 2022 Dec 15.PMID: 36445340
    • New Recommendations of a Height-Based Dosing Regimen of Tobramycin for Cystic Fibrosis in Adults: A Population Pharmacokinetic Analysis. Koloskoff K, Thirion DJG, Matouk E, Marsot A.Ther Drug Monit. 2023 Apr 1;45(2):251-258. doi: 10.1097/FTD.0000000000001021.PMID: 3607075
    • Model Re-Estimation: An Alternative for Poor Predictive Performance during External Evaluations? Example of Gentamicin in Critically Ill Patients. Duong A, Simard C, Williamson D, Marsot A.Pharmaceutics. 2022 Jul 7;14(7):1426. doi: 10.3390/pharmaceutics14071426.PMID: 35890322
    • Risk factors associated with augmented renal clearance in a mixed intensive care unit population: a retrospective study. Bing E, Archambault K, Sananikone A, Nguyen KD, Fang YT, Jabamikos C, Gras C, Marsot A, Duceppe MA, Perreault MM.Int J Clin Pharm. 2022 Dec;44(6):1277-1286. doi: 10.1007/s11096-022-01458-9. Epub 2022 Jul 14.PMID: 35834093
 

Grow Beyond our wildest dreams

With the support of donors like you, at the heart of the Grow Beyond campaign, we are leading healthcare teams towards the opportunities offered by science and new technologies, so that every child, no matter where in Quebec, has access to the unique expertise and know-how of CHU Sainte-Justine. Together, let's join forces for their future.

Grow Beyond with us.

Contact Us

514 345-4931

Légal

© 2006-2014 CHU Sainte-Justine.
All rights reserved.
Terms of Use, Confidentiality, Security

Avertissement

Les informations contenues dans le site « CHU Sainte-Justine » ne doivent pas être utilisées comme un substitut aux conseils d’un médecin dûment qualifié et autorisé ou d’un autre professionnel de la santé. Les informations fournies ici le sont à des fins exclusivement éducatives et informatives.

Consultez votre médecin si vous croyez être malade ou composez le 911 pour toute urgence médicale.

CHU Sainte-Justine